XETRA - Delayed Quote EUR

Gilead Sciences, Inc. (GIS.DE)

89.04

-0.02

(-0.02%)

At close: January 24 at 5:35:36 PM GMT+1

Why Gilead Sciences (GILD) Is One of the Best Humane Stocks to Invest in Now?

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best humane stocks to invest in now. In recent years, the investment landscape has seen a significant shift towards socially responsible investing strategies. […]

Insider Monkey yesterday

GILD
GILD vs. ALNY: Which Stock Is the Better Value Option?

GILD vs. ALNY: Which Stock Is the Better Value Option?

Zacks 2 days ago

ALNY

GILD
Exploring High Growth Tech Stocks in January 2025

The United States market has experienced a notable upswing, climbing by 3.8% over the past week and achieving a 24% increase over the last year, with earnings forecasted to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these positive market trends.

Simply Wall St. 3 days ago

BEIGF

ONC

GILD
Why Gilead Sciences (GILD) Outpaced the Stock Market Today

The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.

Zacks 4 days ago

GILD

^GSPC
Is Gilead Sciences (GILD) Among Billionaire Steve Cohen’s Top Stock Picks?

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other Billionaire Steve Cohen’s top stock picks. Steve Cohen is one of the most prominent and successful hedge fund managers in the world, known […]

Insider Monkey 4 days ago

GILD
Can Gilead Sciences Sustain Its Growth Momentum in 2025?

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.

Zacks 5 days ago

GILD
House of the Week: A Riverfront Retreat in Southeastern Connecticut

The sellers never planned on owning the 30.7-acre property in Lyme, but bought it after a boat deal fell through. Now it’s asking $15 million.

The Wall Street Journal 8 days ago

GILD
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences

Salesforce, Shell and Gilead Sciences are included in this Analyst Blog.

Zacks 8 days ago

GILD

SHEL

CRM
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others

Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc (SHEL) and Gilead Sciences, Inc. (GILD).

Zacks 9 days ago

GILD

SHEL

GM
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best NASDAQ dividend stocks to buy. The NASDAQ, heavily comprised of technology stocks, has been on a consistent upward trajectory for some years. […]

Insider Monkey 9 days ago

GILD
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Zacks 9 days ago

GILD
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Gilead Sciences (GILD) closed at $92.38, marking a +1.52% move from the previous day.

Zacks 10 days ago

GILD

^GSPC
Gilead Sciences, US government settle patent case over HIV prevention drugs

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court. The settlement follows a victory for Gilead in a 2023 jury trial on the government's patent infringement allegations. Gilead General Counsel Deborah Telman said in a statement that the agreement "allows Gilead to continue to focus its resources on its mission to discover, develop, and deliver innovative therapeutics to people with life-threatening diseases."

Reuters 10 days ago

GILD
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies

Gilead gains global rights to oral STAT6 treatments.

GuruFocus.com 12 days ago

GILD
Gilead and LEO Pharma link on programmes for inflammatory conditions

LEO Pharma is eligible to receive up to $1.7bn in total payments, which include a $250m upfront payment.

Pharmaceutical Technology 12 days ago

GILD
Gilead, LEO Pharma partner to develop programs for inflammatory diseases

The Danish company will be eligible to receive up to $1.7 billion in payments which include an upfront payment of $250 million from Gilead. In return, Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 (signal transducer and activator of transcription 6) program. Targeting STAT6 has shown potential preclinically to treat a broad population of patients with inflammatory conditions such as atopic dermatitis, asthma, and COPD, the statement said.

Reuters 14 days ago

GILD
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

FOSTER CITY, Calif. & BALLERUP, Denmark, January 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.

Business Wire 14 days ago

GILD
Morgan Stanley upgrades Gilead on HIV treatment growth

Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.

Investing.com 15 days ago

GILD
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

Zacks 16 days ago

GILD

^GSPC
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Galapagos (GLPG) said Wednesday that it plans to split into two entities, with a new company, or Spi

PREMIUM
MT Newswires 17 days ago

GILD

GLPG.AS

Performance Overview

Return	GIS.DE	S&P 500
YTD	-0.58%	+3.29%
1-Year	+26.91%	+25.42%
3-Year	+67.60%	+38.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gilead Sciences, Inc. (GIS.DE)

Why Gilead Sciences (GILD) Is One of the Best Humane Stocks to Invest in Now?

GILD vs. ALNY: Which Stock Is the Better Value Option?

Exploring High Growth Tech Stocks in January 2025

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

Is Gilead Sciences (GILD) Among Billionaire Steve Cohen’s Top Stock Picks?

Can Gilead Sciences Sustain Its Growth Momentum in 2025?

House of the Week: A Riverfront Retreat in Southeastern Connecticut

The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences

Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others

Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Gilead Sciences, US government settle patent case over HIV prevention drugs

Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies

Gilead and LEO Pharma link on programmes for inflammatory conditions

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Morgan Stanley upgrades Gilead on HIV treatment growth

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Performance Overview